Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Formularies Would Be Authorized But Restricted Under Senate Medicare Bill

Executive Summary

The Senate Finance Medicare drug coverage bill includes language dictating that beneficiaries cannot be forced to pay a higher copay for a non-formulary product if it is determined to be medically necessary
Advertisement

Related Content

USP To Help Set Formulary Rules Under Medicare Rx Bill
PBM, Chain Drug Summer Lobbying Focuses On Mail-Order Rx In Medicare
Medicare Rx Should Cover Dual-Eligibles, Merck Says; Industry Applauds Bill
Pfizer Medicare Message: “Safeguards” Critical, Rx Growth Will Follow
Merck Looks Past Medicare: Next Up, Covering The Uninsured
Medicare Rx Card: Will Drug Discounts Be Permanent Program Fixture?
P&T Cmte. Anonymity Reduces Bias, Caremark Says; A Model For Medicare?
Merck/Medco firewall holding up
Senate AWP Plan Directs HHS To Determine “Market Price” For Chemotherapy
Medicare Rx Debate Will Define Formularies; Pfizer Takes Aim At Tiers
Advertisement
UsernamePublicRestriction

Register

PS041962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel